...
机译:靶向Met基因用于治疗非小细胞肺癌
Department of Medical Oncology Medical Oncology Unit 1 Fondazione IRCCS Istituto Nazionale;
Medical Oncology Unit University Hospital of Parma Italy;
Department of Medical Oncology Medical Oncology Unit 1 Fondazione IRCCS Istituto Nazionale;
Department of Medical Oncology Medical Oncology Unit 1 Fondazione IRCCS Istituto Nazionale;
Laboratory of Molecular Pharmacology Institute for Cancer Research and Treatment and Department of;
Department of Medical Oncology Medical Oncology Unit 1 Fondazione IRCCS Istituto Nazionale;
Medical Oncology Unit University Hospital of Parma Italy;
Hepatocyte growth factor; Kinase inhibitors; MET; NSCLC; Targeted therapies;
机译:靶向MET基因治疗非小细胞肺癌
机译:靶向治疗联合培美曲塞或多西紫杉醇作为晚期非小细胞肺癌患者二线治疗的疗效:一项14项随机对照试验的荟萃分析
机译:在非小细胞肺癌的治疗中,靶标剂量的剂量异质性和调强放疗的剂量会逐步增加。
机译:基于主成分分析的无监督特征提取对非小细胞肺癌细胞株重编程过程中基因表达和启动子甲基化的综合分析
机译:EGFR-TKIs在非小细胞肺癌治疗中的有效性:一项荟萃分析。
机译:HOX转录因子是非小细胞肺癌的潜在治疗靶标(靶向肺癌中的HOX基因)
机译:HOX转录因子是非小细胞肺癌的潜在治疗靶标(靶向肺癌中的HOX基因)
机译:目标(肺癌的逆转,遗传评估和治疗的转化方法)